



Substitute Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
20750-044US1Application No.
10/561,101**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

Applicant
Brian Smith, et al.Filing Date
December 16, 2005Group Art Unit
1624**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	7,232,823	6/19/2007	Carpino et al.			
	AB	7,230,024	6/12/2007	Carpino et al.			
	AC	7,230,002	6/12/2007	Thomas et al.			
	AD	7,229,991	6/12/2007	Merla et al.			
	AE	7,227,027	6/5/2007	Qiu et al.			
	AF	7,211,591	5/1/2007	Tajima et al.			
	AG	7,157,466	1/2/2007	McClure et al.			
	AH	7,173,037	2/6/2007	Alonso-Aliza et al.			
	AI	7,105,523	9/12/2006	Stasch et al.			
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AQ	Bos et al., "Novel Agonists of 5HT _{2C} Receptors. Synthesis and Biological Evaluation of Substituted 2-(Indol-1-yl)-1-methylethylamines and 2-(Indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved Therapeutics for Obsessive Compulsive Disorder," J. Med. Chem., Vol. 40, pp. 2762-2769 (1997).
	AR	Cryan et al., "Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine _{2C} Receptors," The Journal of Pharmacology and Experimental Therapeutics, Vol. 295, No. 3, pp. 1120-1126 (2000).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /EL/

Examiner Signature /Erich Leeser/	Date Considered 06/06/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-044US1	Application No. 10/561,101
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith, et al.	
		Filing Date December 16, 2005	Group Art Unit 1624
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AS	Grottick et al., "Studies to Investigate the Role of 5-HT _{2C} Receptors on Cocaine- and Food-Maintained Behavior ¹ ," The Journal of Pharmacology and Experimental Therapeutics, Vol. 295, No. 3, pp. 1183-1191, (2000).
	AT	Guillory, K. "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids," in: Polymorphism in Pharmaceutical Solids, ed. Harry G. Brittan, Vol. 95, pp.202-209, Marcel Dekker, Inc., New York, (1999).
	AU	Martin et al., "5-HT _{2C} Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential," The Journal of Pharmacology and Experiment Therapeutics, Vol. 286, No. 2, pp. 913-924 (1998).
	AV	Morissette et al., "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids," Advanced Drug Delivery Reviews, Vol. 56, pp. 275-300 (2004).
	AW	Vippagunta et al., "Crystalline solids," Advanced Drug Delivery Reviews, Vol. 48, pp. 3-26 (2001).
	AX	West et al., "Solid State Chemistry and its Applications," pp. 1-3; 358-373 (1984).
	AY	Wood et al., "5-HT _{2C} Receptor Antagonists: Potential in Schizophrenia," Drug Development Research, Vol. 58, pp. 88-94 (2001).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /EL/

Examiner Signature /Erich Leiser/	Date Considered 06/06/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	